ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models (2017)
Machado Neto, João Agostinho ; Ribeiro, Renata Scopim; Coelho-Silva, Juan Luiz; Eide, Christopher A.; Fenerich, Bruna Alves; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Scheucher, Priscila Santos; Tognon, Cristina E.; Figueiredo-Pontes, Lorena Lobo; Druker, Brian J.; Rego, Eduardo Magalhães; Traina, Fabiola
Source: Blood. Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Subjects: DOENÇAS HEMATOLÓGICAS, NEOPLASIAS, METFORMINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/4222. Acesso em: 06 jul. 2024. , 2017
APA
Machado Neto, J. A., Ribeiro, R. S., Coelho-Silva, J. L., Eide, C. A., Fenerich, B. A., Fernandes, J. C., et al. (2017). Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/4222
NLM
Machado Neto JA, Ribeiro RS, Coelho-Silva JL, Eide CA, Fenerich BA, Fernandes JC, Alves APNR, Scheucher PS, Tognon CE, Figueiredo-Pontes LL, Druker BJ, Rego EM, Traina F. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/4222
Vancouver
Machado Neto JA, Ribeiro RS, Coelho-Silva JL, Eide CA, Fenerich BA, Fernandes JC, Alves APNR, Scheucher PS, Tognon CE, Figueiredo-Pontes LL, Druker BJ, Rego EM, Traina F. Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/4222
Trabalho de evento-resumo periodico
DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients (2017)
Ribeiro, Renata Scopim; Machado Neto, João Agostinho ; Campos, Paula De Melo; Eide, Christopher A.; Savage, Samantha L.; Lorand-Metze, Irene; Tognon, Cristina E.; Costa, Fernando Ferreira; Druker, Brian J.; Saad, Sara Teresinha Olalla; Traina, Fabiola
Source: Blood. Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Subjects: NEOPLASIAS, DOENÇAS HEMATOLÓGICAS, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/3969. Acesso em: 06 jul. 2024. , 2017
APA
Ribeiro, R. S., Machado Neto, J. A., Campos, P. D. M., Eide, C. A., Savage, S. L., Lorand-Metze, I., et al. (2017). DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/3969
NLM
Ribeiro RS, Machado Neto JA, Campos PDM, Eide CA, Savage SL, Lorand-Metze I, Tognon CE, Costa FF, Druker BJ, Saad STO, Traina F. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3969
Vancouver
Ribeiro RS, Machado Neto JA, Campos PDM, Eide CA, Savage SL, Lorand-Metze I, Tognon CE, Costa FF, Druker BJ, Saad STO, Traina F. DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3969
Trabalho de evento-resumo periodico
IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia (2017)
Coelho-Silva, Juan Luiz; Machado Neto, João Agostinho ; Fernandes, Jaqueline Cristina; Lima, Ana Silvia G. de; Scheucher, Priscila Santos; Rego, Eduardo Magalhães; Traina, Fabiola
Source: Blood. Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Subjects: LEUCEMIA, DOENÇAS HEMATOLÓGICAS, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COELHO-SILVA, Juan Luiz et al. IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/3966. Acesso em: 06 jul. 2024. , 2017
APA
Coelho-Silva, J. L., Machado Neto, J. A., Fernandes, J. C., Lima, A. S. G. de, Scheucher, P. S., Rego, E. M., & Traina, F. (2017). IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/3966
NLM
Coelho-Silva JL, Machado Neto JA, Fernandes JC, Lima ASG de, Scheucher PS, Rego EM, Traina F. IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3966
Vancouver
Coelho-Silva JL, Machado Neto JA, Fernandes JC, Lima ASG de, Scheucher PS, Rego EM, Traina F. IGF signaling predicts outcomes and is a promising target therapy for acute myeloid leukemia [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/3966
Trabalho de evento-resumo periodico
The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms (2017)
Fenerich, Bruna Alves; Machado Neto, João Agostinho ; Alves, Ana Paula Nunes Rodrigues; Campos, Paula de Melo; Fernandes, Jaqueline Cristina; Coelho-Silva, Juan Luiz; Ribeiro, Renata Scopim; Silva,Fernanda B. da; Scheucher, Priscila Santos; Figueiredo-Pontes, Lorena Lobo; Rego, Eduardo Magalhães; Traina, Fabiola
Source: Blood. Conference titles: Annual meeting and Exposition of American Society of Hematology (ASH). Unidades: ICB, FMRP
Subjects: QUIMIOTERAPIA, NEOPLASIAS, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: http://www.bloodjournal.org/content/130/Suppl_1/1253. Acesso em: 06 jul. 2024. , 2017
APA
Fenerich, B. A., Machado Neto, J. A., Alves, A. P. N. R., Campos, P. de M., Fernandes, J. C., Coelho-Silva, J. L., et al. (2017). The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de http://www.bloodjournal.org/content/130/Suppl_1/1253
NLM
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253
Vancouver
Fenerich BA, Machado Neto JA, Alves APNR, Campos P de M, Fernandes JC, Coelho-Silva JL, Ribeiro RS, Silva FB da, Scheucher PS, Figueiredo-Pontes LL, Rego EM, Traina F. The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms [Internet]. Blood. 2017 ; 130[citado 2024 jul. 06 ] Available from: http://www.bloodjournal.org/content/130/Suppl_1/1253

USP Schools

ReP

Filtros

Authors